SK15032000A3 - Maleínan paroxetínu, spôsob jeho výroby a jeho použitie - Google Patents
Maleínan paroxetínu, spôsob jeho výroby a jeho použitie Download PDFInfo
- Publication number
- SK15032000A3 SK15032000A3 SK1503-2000A SK15032000A SK15032000A3 SK 15032000 A3 SK15032000 A3 SK 15032000A3 SK 15032000 A SK15032000 A SK 15032000A SK 15032000 A3 SK15032000 A3 SK 15032000A3
- Authority
- SK
- Slovakia
- Prior art keywords
- paroxetine
- maleate
- solution
- paroxetine maleate
- toluene
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C07D317/64—Oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9807627.6A GB9807627D0 (en) | 1998-04-09 | 1998-04-09 | Novel compounds |
| GBGB9823856.1A GB9823856D0 (en) | 1998-10-30 | 1998-10-30 | Novel compound |
| PCT/GB1999/001106 WO1999052901A1 (en) | 1998-04-09 | 1999-04-09 | Paroxetine maleate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK15032000A3 true SK15032000A3 (sk) | 2001-04-09 |
Family
ID=26313449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1503-2000A SK15032000A3 (sk) | 1998-04-09 | 1999-04-09 | Maleínan paroxetínu, spôsob jeho výroby a jeho použitie |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1073652A1 (zh) |
| JP (1) | JP2002511466A (zh) |
| KR (1) | KR20010042552A (zh) |
| CN (1) | CN1305474A (zh) |
| AP (1) | AP2000001950A0 (zh) |
| AU (1) | AU3433499A (zh) |
| BG (1) | BG104914A (zh) |
| BR (1) | BR9909529A (zh) |
| CA (1) | CA2327450A1 (zh) |
| EA (1) | EA200001050A1 (zh) |
| HU (1) | HUP0103651A3 (zh) |
| ID (1) | ID26879A (zh) |
| IL (1) | IL138920A0 (zh) |
| NO (1) | NO20005037L (zh) |
| PL (1) | PL343378A1 (zh) |
| SK (1) | SK15032000A3 (zh) |
| TR (1) | TR200002939T2 (zh) |
| WO (1) | WO1999052901A1 (zh) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6231833B1 (en) | 1999-08-05 | 2001-05-15 | Pfizer Inc | 2,7-substituted octahydro-1H-pyrido[1,2-A]pyrazine derivatives as ligands for serotonin receptors |
| CH689805A8 (fr) * | 1998-07-02 | 2000-02-29 | Smithkline Beecham Plc | Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant. |
| GB9827387D0 (en) * | 1998-12-11 | 1999-02-03 | Smithkline Beecham Plc | Novel process |
| GB9827431D0 (en) * | 1998-12-11 | 1999-02-03 | Smithkline Beecham Plc | Novel compound |
| GB9914585D0 (en) * | 1999-06-22 | 1999-08-25 | Smithkline Beecham Plc | Novel process |
| NL1017421C2 (nl) | 2001-02-21 | 2002-01-15 | Synthon Bv | Werkwijze voor het vervaardigen van paroxetine. |
| KR100672184B1 (ko) | 2004-09-21 | 2007-01-19 | 주식회사종근당 | 파록세틴의 콜린산 또는 콜린산 유도체 염 |
| ITTO20060143A1 (it) * | 2006-02-28 | 2007-09-01 | Bridgestone Corp | Pneumatico |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1422263A (en) * | 1973-01-30 | 1976-01-21 | Ferrosan As | 4-phenyl-piperidine compounds |
| PT994872E (pt) * | 1997-06-10 | 2001-09-28 | Synthon Bv | Composto de 4-fenilpiperidina |
-
1999
- 1999-04-09 EA EA200001050A patent/EA200001050A1/ru unknown
- 1999-04-09 CN CN99807148A patent/CN1305474A/zh active Pending
- 1999-04-09 SK SK1503-2000A patent/SK15032000A3/sk unknown
- 1999-04-09 TR TR2000/02939T patent/TR200002939T2/xx unknown
- 1999-04-09 CA CA002327450A patent/CA2327450A1/en not_active Abandoned
- 1999-04-09 WO PCT/GB1999/001106 patent/WO1999052901A1/en not_active Application Discontinuation
- 1999-04-09 PL PL99343378A patent/PL343378A1/xx not_active Application Discontinuation
- 1999-04-09 AP APAP/P/2000/001950A patent/AP2000001950A0/en unknown
- 1999-04-09 KR KR1020007011214A patent/KR20010042552A/ko not_active Application Discontinuation
- 1999-04-09 EP EP99915911A patent/EP1073652A1/en not_active Ceased
- 1999-04-09 BR BR9909529-7A patent/BR9909529A/pt not_active Application Discontinuation
- 1999-04-09 ID IDW20002033A patent/ID26879A/id unknown
- 1999-04-09 AU AU34334/99A patent/AU3433499A/en not_active Abandoned
- 1999-04-09 HU HU0103651A patent/HUP0103651A3/hu unknown
- 1999-04-09 JP JP2000543459A patent/JP2002511466A/ja active Pending
- 1999-04-09 IL IL13892099A patent/IL138920A0/xx unknown
-
2000
- 2000-10-06 NO NO20005037A patent/NO20005037L/no not_active Application Discontinuation
- 2000-11-07 BG BG104914A patent/BG104914A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ID26879A (id) | 2001-02-15 |
| BG104914A (en) | 2001-10-31 |
| PL343378A1 (en) | 2001-08-13 |
| WO1999052901A1 (en) | 1999-10-21 |
| CA2327450A1 (en) | 1999-10-21 |
| NO20005037L (no) | 2000-12-05 |
| KR20010042552A (ko) | 2001-05-25 |
| HUP0103651A2 (en) | 2002-08-28 |
| EP1073652A1 (en) | 2001-02-07 |
| AP2000001950A0 (en) | 2000-12-31 |
| NO20005037D0 (no) | 2000-10-06 |
| CN1305474A (zh) | 2001-07-25 |
| BR9909529A (pt) | 2000-12-12 |
| HUP0103651A3 (en) | 2002-12-28 |
| AU3433499A (en) | 1999-11-01 |
| JP2002511466A (ja) | 2002-04-16 |
| IL138920A0 (en) | 2001-11-25 |
| EA200001050A1 (ru) | 2001-04-23 |
| TR200002939T2 (tr) | 2001-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20020035130A1 (en) | Novel compound | |
| US20040242506A1 (en) | Paroxetine glycyrrhizinate | |
| AT7110U2 (de) | Verfahren zur herstellung von amlodipinmaleat | |
| SK15032000A3 (sk) | Maleínan paroxetínu, spôsob jeho výroby a jeho použitie | |
| SK11812000A3 (sk) | Soli paroxetínu, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie | |
| US20040143120A1 (en) | Paroxetine maleate | |
| SK283188B6 (sk) | Spôsob prípravy kryštalickej formy 3/2 hydrátu 7-[(7-(S)- amino-5-azaspiro[2.4]-heptan-5-yl]-8-chlór-6-flór-1-[(1R,2S)-2- flórcyklopropyl]-4-oxo-1,4-dihydrochinolín-3-karboxylovej kyseliny | |
| SK15912000A3 (sk) | Askorbát paroxetínu, spôsob jeho výroby a jeho použitie | |
| SK15902000A3 (sk) | 10-gáforsulfonát paroxetínu, spôsob jeho výroby a jeho použitie | |
| SK17342001A3 (sk) | Polymorfné formy kryštalického (2-benzhydryl-1-azabicyklo- [2.2.2]okt-3-yl)-(5-izopropyl-2-metoxybenzyl)amín-citrátu ako antagonistov receptora NK-1 | |
| MXPA00009884A (en) | Paroxetine maleate | |
| CZ20003722A3 (cs) | Maleat paroxetinu | |
| WO2000008016A1 (en) | Paroxetine salts | |
| MXPA00010435A (en) | Paroxetine 10-camphorsulfonate for treatment of cns disorders | |
| CZ20003941A3 (cs) | 10-KafrsuIfonat paroxetinu pro léčbu poruch centrálního nervového systému | |
| MXPA00010439A (en) | Paroxetine ascorbate | |
| AU2528899A (en) | Salts of paroxetine | |
| CZ20002845A3 (cs) | Soli paroxetinu | |
| CZ20003942A3 (cs) | Askorbat paroxetinu | |
| WO2000078752A1 (en) | Process for the production of paroxetine hydrochloride | |
| AT5462U1 (de) | Verfahren zum herstellen von amlodipinmaleat |